Cargando…
Asthma and COVID-19: In Defense of Evidence-Based SABA
There have recently been major objections to the use of short-acting beta-agonist (SABA) in episodic acute asthma culminating in a call for replacing SABA with combination of inhaled corticosteroids and long-acting beta-agonists despite little evidence supporting this point of view. It is regrettabl...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575826/ https://www.ncbi.nlm.nih.gov/pubmed/33116658 http://dx.doi.org/10.2147/JAA.S279061 |